Drug Discovery@nature.com 14 March 2014

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS 14 March 2014 News Analysis Research Highlights Research & Reviews Careers Nature Reviews Drug Discovery is on Twitter Advertisement nature.com webcasts Macmillan Science Communication presents a custom webcast: Biomarkers and immunoassays: Enhancing your research with multiplex cytokine profiling. Thursday 20 March at 8am PDT / 11am EDT / 3pm GMT / 4pm CET  Register for the free webcast followed by a live Q & A session  Sponsored by:     News Top Markets, venture investors and big pharma interest in RNAi soars doi:10.1038/nbt0314-203 Improved delivery systems and promising clinical data are driving renewed interest and investment in RNAi therapeutics. Full Text First integrin inhibitor since Tysabri nears approval for IBD doi:10.1038/nbt0314-205 Vedolizumab, a drug for inflammatory bowel disease, is set to become the first integrin inhibitor to gain approval since the multiple sclerosis therapy natalizumab a decade ago. Full Text As drug target reemerges, the question is to block or stimulate it doi:10.1038/nm0314-222 Efforts to target the 'mysterious' angiotensin II receptor type 2 currently involve both antagonists for pain relief and agonists to stimulate tissue repair and possibly reduce hypertension. Full Text An audience with... John Reed doi:10.1038/nrd4262 John Reed, Head of Pharma Research & Early Development at Roche, discusses his plans to tweak the therapeutic focus, clinical development strategy and externalization of innovation at Roche. Full Text Analysis Top Liver X receptor marks the spot doi:10.1038/scibx.2014.243 The finding that LXR agonists can treat metastatic melanoma opens up new avenues for such compounds that were discontinued in cardiovascular disease. Full Text Systemic lupus erythematosus and lupus nephritis doi:10.1038/nrd4220 The likely market impact of the late-stage pipeline for systemic lupus erythematosus (SLE) and lupus nephritis (LN), which contains biologics and small-molecule drugs for a broad range of targets. Full Text Research Highlights Top Inflammatory disorders: Monocytes derailed by microparticles doi:10.1038/nrd4263 Microparticles that target inflammatory monocytes can dampen inflammation and alleviate symptoms in several mouse models of immune-mediated disease. Full Text Vascular disease: A new way to starve vascular endothelial cells doi:10.1038/nrd4264 Partial inhibition of glycolysis with a small-molecule drug could ameliorate pathological angiogenesis, which occurs in various diseases including cancer. Full Text Neurological disorders: Presynaptic glycine receptors become a startling target doi:10.1038/nrd4265 A cannabinoid derivative that seems to target presynaptic glycine receptors could have therapeutic potential in startle disease. Full Text Research & Reviews Top REV-ERB and ROR nuclear receptors as drug targets doi:10.1038/nrd4100 A Review on the development of ligands to target two classes of nuclear receptors — the REV-ERBs and RORs — and their possible use in treating disorders related to metabolism, immune function and the circadian rhythm. Full Text Drugging the p53 pathway: understanding the route to clinical efficacy doi:10.1038/nrd4236 In this Review, Lane and colleagues provide an overview of the different therapeutic approaches to targeting the p53 pathway in cancer and discuss the state of development of p53 pathway modulators. Full Text Opinion: Targeting tumour-supportive cellular machineries in anticancer drug development doi:10.1038/nrd4201 The advantages and limitations of agents that target tumour-supportive cellular machineries — such as the proteasome, heat shock protein complexes and proteins involved in chromatin modifications — which are emerging as a new wave of anticancer drugs. Full Text Progress: The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells doi:10.1038/nrmicro3200 Veronique Dartois describes new methods to quantify and image anti-tuberculosis drug distribution in infected lung tissue and mycobacterial cells, and explores how this technology could be used to design optimized multidrug regimens. Full Text Drug Discovery JOBS of the week Postdoctoral Research Fellow in Nanomedicine and Drug Delivery Wayne State University Entrepreneurial Fellowship in Drug Development Program The Centre for Drug Research and Development PhD Studentship in Molecular Drug Resistance starting October 2014 Institute of Cancer Research (ICR) Mass Spectrometry / Drug Development Mount Sinai Medical Center/Icahn School of Medicine at Mount Sinai PhD studentship - Computational genomics of acquired drug resistance in cancer University of Kent More Science jobs from Drug Discovery EVENT CHI's Structure-Based Drug Design 21.05.14 Boston, USA More science events from Careers Top Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text Top Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.